

DAFTAR PUSTAKA

- Abdulrahman H, Dima J, Faisal M S, Waleed A H, Ayman A A, Ahmed A A. 2011. Effect of Interferon Treatment on hearing of Patients with Chronic Hepatitis C. *Saudi Journal Gastroenterol.* Vol 17 (2): 114-8
- Ansaldi, Filippo, Orsi, Andrea., Sticchi, Laura, Bruzzone, Bianca, Icardi, Giancarlo. 2014 Hepatitis C Virus in The New Era: Perspectives in Epidemiology, Prevention, Diagnostics and Predictors of Response to Therapy. *World Journal of Gastroenterology.* Vol 20 (29)
- Arnaud, P. 2002. Les différents interférons : Pharmacologie, mécanismes d'action, tolérance et effets secondaires. *La Revue de Médecine Interne.* 23: 449S-458S
- Ashley M, Onyema M. 2018. Pegylated interferon alpha 2A for the treatment of hepatitis C virus infection. *Expert opinion on drug metabolism and toxicology.* 14(2); 219-227
- Asnis GM, De La Garza R. 2006. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. *J Clinic Gastroenterol.* 40 (4): 322- 335
- AW Khan, S Nisar, SA Ali, F Ahmad. 2016. Effect Of Interferon Therapy On Heart. *J Ayub Med Coll Abbottabad.* Vol 28: 276-280.
- Benova, Lenka., Mohamoud, Yousra A., Calvert, Clara., & Abu-Raddad, Laith J.2014. Vertical Transmission of Hepatitis C Virus: Systemic Review and Metaanalysis, *Clinical Infectious Diseases.* 59(6): 765-773.
- Calvaruso V, Mazza M, Almasio P L. 2011. Pegylated-interferon- α 2a in clinical practice: how to manage patients suffering from side effects. *Expert Opinion on Drug Safety.* 10(3): 429–435.
- Cetin Karaca, Ozlem M S, Bulent B, Asli C O, Suut G, Esra A, Sami E, Filiz A, Kadir D, Fatih B, Sabahattin K. 2013. Efficacy of pegylated interferon- alpha treatment for 24 months in chronic delta hepatitis and predictors of respons. *International Medical Press.* 18: 561-566
- Chen H L, Chung F H, Chun J L, Chia Y D, Cheng C L, Jee-Fu H, Peir H H, Hung B S.,Meng K S, Shih I C, Jou W L, Sheng S Y, Tung H S, Hung C Y, Pei J C, Ding S c, Wan L C, Ming L Y, Jia H K. 2017. Pegylated Interferon Alpha 2A or without low dose ribavirin for treatment- naïve patients with hepatitis c virus genotype 1 receiving hemodialysis. *Annal of internal medicine.* Vol 159: 729-738
- Dan A A, Martin L M, Crone C, Ong J P, Farmer D W, Wise T, Younossi Z M.2006. Depression anemia and health related quality of life in chronic hepatitis C. *Journal of hepatology.* 44(3): 491-498
- Davis G L.1999. Combination Treatment with Interferon and Ribavirin for Chronic Hepatitis C. *Clinics in Liver Disease.* 3(4), 811–826.
- Dosouky, Ibtesam., Elhawari, Soha., Emara, Mohamed., Hamed, Emad.2014. Types and Predictors of Interferon /Ribavirin Induced Cardiac Complications in The Egyptian Patients With Chronic Hepatitis C Virus. *Faculty of Medicine, Zagazig University Egypt.* Vol 20: 643-653.

- Don J S, Han C L, Kwan S B, Mong C, Young O K, Won Y T, Chae Y C, Kwang C K, Young S L. 2013. Efficacy and Safety of Pegylated Interferon alpha2A in Patients, with Lamivudine – Resistant HBeAG-Positive Chronic Hepatitis B. *International Medical Press*. 18 :765-773
- El-Serag, Hashem B.2012. Epidemiology of Viral Hepatitis and Hepatocellulae Carcinoma, HHS Author Manuscript. 142(6): 1264-1273.
- Eleanor L M. 2010. Preclinical and Clinical Development of Pegylated Interferon. *Journal of Interferon & Cytokine Research*. 30 (8): 581-598
- Elif D Kartal, Saygin N A, Ilhan O, Gaye U. 2007. Adverse effects of high – dose interferon -alpha 2A treatment for chronic hepatitis B. *Advances in therapy*. 24: 963
- Fabrizio F, Vivek D, Piergiorgio M, Paul M. 2010. Pegylated interferon monotherapy of chronic hepatitis c in dialysis patients: Meta – analysis of clinical trials. *Journal of Medical Virology*. 82: 768-775
- Fattovich, Giovanna. 2003. Natural History of Hepatitis B. *Journal of Hepatology*,. 2003; Vol 39: 50-58.
- Francis E Lotrich. 2013. Psychiatric Clearance for Patients Started on Interferon Alpha Based Therapies. *Am Psychiatry*.2013; 170: 6
- Gulden E.K., Turgut K., Kutbetiin D., Erol K, 2011. The Effects of Pegylated Interferon/Lamivudin Therapy on Auditory Functions in Patients with Hepatitis b, *Auris Nasus Larynx International Journal of ORL&HNS*, Vol 38, 312-318
- Gökhan K., George N.D., Yilmaz Ç., Kalliopi Z., Thomas b., Andreas E., Stefan Z., Fehmi T., Kendal Y.A., Mithat B., Hans P.D., Hakan. B., Michael M., Heiner. W, & Cihan Y. 2012. Pegylated Interferon Based Treatment in Patients With Advanced Liver Disease due to Chronic Delta Hepatitis. *Turk Journal Gastroenterol*. Vol.23(5): 560-568
- Harahap, Agustina. 2016. Pengaruh Faktor Predisposing, Enabling, dan Reinforcing Terhadap Pemberian Imunisasi Hepatitis B Pada Bayi di Puskesmas Bagian Batu Kecamatan Bagian Sinembah Kabupaten Rokan Hilir. *Jurnal Ilmiah Penelitian Kesehatan*, Vol 1, 1.
- Haris P, Murali S R, Martin M, Sonu D, Paul M. 2012. Depression and pegylated Interferon – Based Hepatitis C Treatment. *International Journal of Interferon, Cytokin, and Mediator Research*. Vol: 4, 25-23
- Hung B S, Meng K S, Shih I C, Jou W L, Sheng S Y, Tung H S, Hung C Y, Pei J C, Ding S C, Wan L C, Ming L Y, Jia H K. Pegylated Interferon- Alfa2A or Without Low Dose Ribavirin for Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. *Annal of Internal Medicine*. Vol.159: (729-738)
- HS, Te., & DM, Jensen. 2010. Epidemiology of Hepatitis B and C Viruses: A Global Overview. *Clin Liver Dis*, Vol 14, 1-21.
- Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J . 2002. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. *Mol psychiatry*. 7:942-7.

- Hubert S, Michael C, Sammy S. 2011. Management of hepatitis c antiviral therapy adverse effect. *Current hepatology reports*. 10: 33-40
- Hofstraat, S. H. I., Falla, A. M., Duffell, E. F., Hahne, s. j M., Amatogauci, A. J., Veldhuizen, I. K., & Tavoschi, L, 2017. Current Prevalence of Chronic Hepatitis B and C Virus Infection in The General Population, Blood Donors and Pregnant Women in the EU/EEA: a Systemic Review. *Epidemiology amd Infection*, 145(14), 2873-2885.
- A.F.,Christofoli. B., & Paulo R.L.A, 2016. Impact of The Pegylated Interferon and Ribavirin Therapy on The Treatment Related Mortality of Patients with Cirrhosis Fue to Hepatitis C Virus. *Rev Inst Med Trop Sao Paulo*. 58:37
- Kan K, Takashi A, Kosaku N, Ikuto M, Ryoichi, Namiki I, Masanori A, Chikao Y, Fumi K, Naoki H, Yoahihiro T, Etsuro O, Kazuhiko H, Masaki N, Hiroshi K, Masanor K, Hiroyuki K, Norisato, Hideki, Misaki M, Michio I, Tadao A. Multicenter study of pegylated interferon alpha-2A monotherapy for hepatitis C virus infected patients on hemodialysis: Reach study. *Therapeutic Apheresis and Dialysis*. 2014; 18(6): 603-611
- Kelly F N D, Angelo A M, Christiane V T, Fernanda W O, Leandro C, Alberi A F, Christofali B, Paulo R L A. Impact of the pegylated interferon and ribavirin therapy on the treatment related mortality of patients with cirrhosis due to hepatitis c virus. *Revista do instituto de medicina tropical de sao Paulo*. 2016; 58: 37
- Kirkwood, J. M., Bender, C., Agarwala, S., Tarhini, A., Shipe-Spotloe, J., Smelko, B., Stover, L. (2002). Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy. *Journal of Clinical Oncology*, 20(17), 3703–3718
- Kninghton, Sarah., DipClinPharm., & MRPharms. 2013. Hepatitis C Management. *Clinical Pharmacist*, Vol 5, 103-109.
- Kokoglu O F, Ucmak H, Hosoglu S, Cetinkaya A, Kantarceken B, Buyukbese M A, Isik IO. 2006. Efficacy and tolerability of pegylated interferon alpha-2a in hemodialysis patients with chronic hepatitis c. *Journal of gastroenterology and hepatology*.21 (3): 575-580
- Maryam A, Jason G, Gail V M, Kathy P, Barbara Y, Carolyn D, Andrew R L, Ingrid V B, John M K, Margaret H, Gregory J D, Paul S H. Effect of pegylated interferon alpha-2a treatment on mental health during recent hepatitis c virus infection. *Journal of gastroenterology and hepatology*. 2012; 27: 957-965
- M. A., & Isik, I. O. (2006). Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. *Journal of Gastroenterology and Hepatology*, 21(3), 575–580.
- Ingrid V.B., John M.K., Margaret H., Gregory J.D., & Paul S.H, 2012. Effect of Pegylated Interferon-Alpha-2A Treatment on Mental Health During Recent Hepatitis C Virus Infection. *Journal of Gastroenterology and Hepatology*, Vol 27: 957-965
- Mendes-Corrêa, M. C. J., Bittar, R. S. M., Salmito, N., & Oiticica, J, 2011. Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil. *The Brazilian Journal of Infectious Diseases*, 15(1),87-89.

- Michel B, Victor P, Valentin C, Lilia C, Pavline J, Jeffrey, A, Peter S, Frederic L G, Emmanuel G, Adalbert K H, Hadi K, Michael R, Andrew V. Safety and efficacy of REP 2139 and pegylated interferon alpha-2A for treatment- naïve patients with chronic hepatitis b virus and hepatitis d virus co-infection (REP 301and REP 301-LTF): a non randomized, open label, phase 2 trial. *Lancet Gastroenterol Hepatol*. 2017; 2 (12): 877-889
- L.G., Emmanuel G., Adalbert. K., Hrvoje., Hadi K., Michael R., & Andrew V., 2017. Safety and efficacy of REP 2139 and Pegylated interferon alfa-2A for Treatment-Naïve Patients with Chronic Hepatitis B Virus and hepatitis D Virus Co-Infection (REP 301 and REP301-LTF): a Non Randomised, Open Label, Phase 2 trial. *Lancet Gastroenterol Hepatol*, Vol.
- Mohamed M.H Al-ahmer & Amr Mohamed Elmistkawy, 2013. Otological Side-Effects of Pegylated Interferon Therapy For Chronic Hepatitis C Patients Are Evident But Temporary And Correctable Effects, 2013. *AAMJ*, Vol. 11(4)
- Mario E, Jesus H, Maria D A, Fernando C, Carlos C, Fabrizio F. Pegylated interferon alone or with ribavirin for chronic hepatitis c in haemodialysis population. *Kidney blood Press Res*. 2015; 40(3): 258-65
- Muhammad A.M., Asif Mehmood, Muhammad A. F., Ghias U.N.T, Israr U.H.T, 2016. Hypothyroidism in Hepatitis C Patients On Pegylated Interferon Therapy. *J Ayub Med coll Abbottabad*. Vol 20(4), 706-708
- MS Chang, & MH Nguyen. 2017. Epidemiology of Hepatitis B and The Role of Vaccination. *Best Pract Res Clin Gastroenterol*, Vol 31(3), 239-247.
- Mukherjee, Ronita., Burns, Andrew., Rodden, Diane., Chang, Frances., Chaum, Manita., Garcia, Nancy., Bollipalli, Nikitha., Niemz, Angelika. 2015. Diagnosis and Management of Hepatitis C Virus Infection. *Journal of Laboratory Automation*, Vol 20, 519-538.
- Muljono, David H. 2017. Epidemiology of Hepatitis B and C in Republic of Indonesia. *Euroasian J Hepatogastroenterol*, Vol 7(1), 55-59.
- Mustika, Sifa, Hasanah, Dian, 2018. Prevalence of Hepatitis B Infection in Pregnant Women in Malang. *Jurnal Kedokteran Brawijaya*. Vol 30(1).
- M R Kraus, A Schafer, K Schottker, C Keicher, B Weissbrich, I Hofbauer, M Scheurlen. 2008. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomized, double blind, placebo-controlled trial. *BMJ Publishing Group & British Society of Gastroenterology*. Vol 57 (4)
- MW Fried. 2002. Side Effects of Therapy of Hepatitis C and Their Management. *Hepatology Journal*. Vol 36, 237-244.
- Mysore, Krupa R, Leung, Daniel H. 2018. Hepatitis B and C, *Clinics in Liver Disease*, Vol 22, Issue4, 703-722.
- Naz, Hasan, Aslan, Vahap. 2009. Treatment of Autoimmune Thrombocytopenia in a Case of Chronic hepatitis C With ursodeoxycholic Acid, *Journal Infect Dev Countries*, 3(8), 644-646.

- Nikolina B J, Marijana G, Jasna S, Valentina C M, Bosilijka I, Sanjin R, Nilenka S, Rajko O, Irena H, Dragan L, Boris V, Petar K. Pegylated interferon for treatment of chronic hepatitis c in hemodialysis patients in Croatia, kidney blood pressure research. 2011; 34: 53-57
- Nilenka.S., Rajko O., Irena H., Dragan L., Boris.V.,& Petar.K, 2011. Pegylated Interferon for Treatment of Chronic Hepatitis C in Hemodialysis Patients in Croatia, Kidney Blood Pressure Research, Vol. 34: 53-57
- Nurdjanah, Siti, 2001. Therapy for Chronic Viral Hepatitis, The Indonesiam Journal of Gastroenterology, Hepatology, and Digestive Endescopu, Vol 2(1)
- Peck–Radosavljevic, M., Wichlas, M., Homoncik–Kraml, M., Kreil, A., Hofer, H., Jessner, W., ... Ferenci, P. (2002). Rapid suppression of hematopoiesis by standard or pegylated interferon- α . *Gastroenterology*, 123(1), 141–151
- Pramita, Prasna., Gani, Rino A., & Sulaiman, Ali. 2005. Treatment of Chronic Hepatitis B, The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, Vol 6(1).
- Re, Vincent. 2017. Extrahepatic Complications of Hepatitis C Virus Infection in HIV and The Impact of Successful Antiviral Treatment. *Clinical Infectious Diseases*, Vol 4, 498-500.
- Russo, Mark W, Fried, Michael W. 2003. Side Effects of Therapy for chronic hepatitis C. *Gastroenterology Journal*, Vol 124: 1711-1719.
- Sanjaya K S, Chandra S L, Shawnette P, Shobhana C, Susan W. 2010. Equally Poor Outcomes to Pegylated Interferon – based Therapy in African American and Hispanics with Chronic Hepatitis C Infection. *J Clinic Gastroenterol*. Vol. 44 No.2
- Serrano-Villar S, Quereda C, Moreno A, Pérez-Elías M J, Casado J L, Royuela A, Moreno S. (2013). Neutropenia During Therapy With Peginterferon and Ribavirin in HIV-Infected Subjects With Chronic Hepatitis C and the Risk of Infections. *Clinical Infectious Diseases*, 57(3), 458–464
- Seyam M, Freshwater D, O'Donnell K, Mutimer J. 2005. Weight Loss During Pegylated Interferon and Ribavirin Threatment of Chronic Hepatitis C. *Journal of Viral Hepatitis*, Vol 12, 531-535.
- Sherman, Morris, Shafran, Stephen, Burak, Kelly, Doucette Karen, Wong, Winnie, Girgrah, Nigel, Yoshida, Eric, Renner, Eberhard., Wong, Philip, Deschenes, Marc. 2007. Management of Chronic Hepatitis B: Consensus Guidelines. *Canadian Journal of Gastroenterology*, Vol 21, 5C-24C.
- Spearman, C. W., Dusheiko, G. M., Hellard, M., & Sonderup, M. (2019). Hepatitis C. *The Lancet*, Vol 394, 1451–1466.
- S S, M R Abu Hassan., A Abdullah., B P Ooi., T Korompis., M I Merican. 2010. Safety and Efficacy of an Escalating Dose Regimen of Pegylated Interferon alpha 2B in The Treatment of Haemodialysis Patients with Chrronic Hepatitis C. *Journal of Viral Hepatitis*, 2010. Vol 17, 410-418
- Sunbul, Mustafa. 2014. Hepatitis B virus genotypes: Global distribution and clinical importance. *World J Gastroenterol*, Vol 20(18), 5427- 5434.

- Tan S S, Abu Hassan M R, Abdullah A, Ooi B P, Korompis T T, Merican M I. Safety and Efficacy of an Escalating Dose Regimen of Pegylated Interferon alpha 2B in The Treatment of Haemodialysis Patients with Chronic Hepatitis C. *Journal of Viral Hepatitis*. 2010; Vol 17, 410-418
- Teresa S., Massimo F., Evangelista S., Paulo T., Sergio B., Paolo F., Mario T., Giovanni D P., Nicoletta M., Eligio P., Gioacchino A. 2014. Acute Hepatitis C: A 24 – Week Course of Pegylated Interferon Alpha 2b Versus a 12- Week Course of Pegylated Interferon Alpha -2B Alone or with Ribavirin. *Official Journal of The American Association for The Study of Liver Disease*. Vol. 59, No. 6
- TC, Schreuder., HC, Gelderblom., CJ, Weegink., D, Hamann., HW, Reesink., JH, Devries., JB, Hoekstra., & Pl, Jansen, 2007. High Incidence of Type 1 Diabetes Mellitus During or Shortly After Treatment With Pegylated Interferon Alpha for Chronic Hepatitis C Virus Infection, *AMC Liver Centre*, 28(1), 39-46).
- Trepo C, Chan H L, Lok A. 2014. Hepatitis B Virus Infection. *Lancet*, Vol 384, 2053-2063.
- Trisnaningtyas, Rahmannisa Wikan., Sari, Chynthia Pradiftha Sari., & Setyaningrum, Ndarum, 2017. Evaluasi Terapi Pada Pasien Hepatitis B di RSUP Dr. Sardjito Yogyakarta, *Jurnal Ilmiah Farmasi Universitas Islam Indonesia*, Vol 13(1).
- Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. *Am J Gastroenterol*. 1994; 89 (3): 399-403
- Y., Fumi.k., Naoki. H., Yoahihito T., Etsuro. O., Kazuhiko H., Masaki., N., Hiroshi K., Masanor. K., Hiroyuki K., Norisato., Hideki., Misaki. M., Kenichiro. S., Takashi H., Hideki. H., Hisroshi W., Tsuyoshi N., Hirohito. T., Michio i. & Tadao. A. 2014. Multicenter Study of Pegylated Interferon Alpah- 2A Monotherapy for Hepatitis C Virus-Infected Patients on Hemodialysis: Reach Study. *Therapeutic Apheresis and Dialysis*, Vol 18(6): 603-611
- Z M.2006. Depression, anemia and health-related quality of life in chronic hepatitis C. *Journal of Hepatology*. 44(3): 491–498
- Zampino, Rosa., Boemio, Adriana., Sagnelli, Caterina., Alessio, Loredana., Adinolfi, Luigi Elio., Sagnelli, Evangelista., 2015. Hepatitis B Virus Burden in Developing Countries, *World Journal Gastroenterology*, Vol 21(42), 11941- 11953.
- Zehui Y, Ke F, Yi F, Xiaohong W, Qing M, Guohong D, & Yuming W, Don J S, Han C L, Kwan S B, Mong C, Young O K, Won Y T, Chae Y C, Kwang C K, Young S L. 2013. Efficacy and Safety of Pegylated Interferon alpha2A in Patients, with Lamivudine – Resistant HBeAG-Positive Chronic Hepatitis B. *International Medical Press*. 18:765-773
- Zhang, Zhiqiao., Li, Jing., Wang, Peng., He, Tingshan., Ouyang, Yanling., & Huang, Yiyang, 2017. Nomogram for Cirrhosis in Patients with Chronic Hepatitis B: A Simple Self-Assessed Scale For Individual Risk of Cirrhosis, *Scientific Reports*, 7(1).
- Zohreh Jadali. 2013. Autoimmune Thyroid Disorder in Hepatitis c Virus Infection: Effect of Interferon Therapy. *Indian Journal of Endocrinology and Metabolism*. Vol 17 (1)
- Zorana P., Dragon D., Nadja P.M., Olivera V., & Mirosława J.G, 2011. Depressive Symptoms in Patients With Hepatitis C Treated With Pegylated Interferon Alpha Therapy: A 24 Week Prospective Study, *Psychiatri Danubina*, Vol 23(4): 370-377